SingleGrowth Hormone

CJC-1295 DAC 2mg

Long-acting GHRH synthetic analog bound to albumin via DAC to sustain continuous GH and IGF-1 elevation in research models.

Mechanism

CJC-1295 DAC targets pituitary somatotroph GHRH receptors while using an albumin-binding DAC moiety to prolong systemic circulation and maintain continuous growth hormone release.

Dosing

Standard research protocols initiate administration at 300 mcg delivered twice weekly.

Reconstitution

Inject 2.0 mL of bacteriostatic water slowly down the vial wall to obtain a 1 mg/mL (1,000 mcg/mL) concentration.

Storage

Keep unmixed lyophilized vials at -20 °C and store the reconstituted solution refrigerated between 2 °C and 8 °C without freezing.

Mix & measure CJC-1295 DAC 2mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure CJC-1295 DAC 2mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration1.00mg/mL

Draw volume0.300mL

On the syringe30.0units

Total doses in vial: 6.7

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	300 mcg (0.3 mg) twice weekly	30 units (0.30 mL)
Weeks 3–4	500 mcg (0.5 mg) twice weekly	50 units (0.50 mL)
Weeks 5–6	750 mcg (0.75 mg) twice weekly	75 units (0.75 mL)
Weeks 7–12	1000 mcg (1 mg) twice weekly	100 units (1.0 mL)

Reconstitution Steps

1
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
2
Release it slowly down the vial's inner wall to limit foaming.
3
Swirl or roll gently until fully dissolved — don't shake.
4
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.

Supplies Needed

Peptide Vial

2 mg CJC-1295 DAC lyophilized powder container

Insulin Syringes (U-100)

1 mL syringes for precise volume extraction and measurement

Bacteriostatic Water

Sterile diluent containing 0.9% benzyl alcohol for multi-dose reconstitution

Alcohol Swabs

Antiseptic wipes to sanitize the rubber vial stopper and injection area

Why researchers study it

GH & IGF-1 support

Fat metabolism / lipolysis

Recovery & tissue repair

Sleep & slow-wave sleep

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

CJC-1295 DAC is an engineered synthetic secretagogue derived from growth hormone-releasing hormone (GHRH). By incorporating the Drug Affinity Complex (DAC), this molecule covalently couples with circulating endogenous albumin, extending its biological half-life significantly beyond that of unmodified native peptides. Consequently, it circumvents the rapid enzymatic degradation typically observed with short-acting somatotropic signaling molecules. In preclinical research models, CJC-1295 DAC promotes a steady, non-pulsatile elevation of growth hormone release often described in pharmacological literature as a sustained secretion or baseline plateau. This steady-state signaling cascades into downstream hepatic production of insulin-like growth factor 1 (IGF-1), permitting researchers to investigate prolonged endocrine axis activation without necessitating high-frequency administration. Investigation into CJC-1295 DAC primarily centers on endocrine signaling kinetics, cellular metabolism, tissue repair dynamics, and somatotrophic tone. Because clinical trials were historically halted, this peptide remains purely an investigational agent without regulatory approval for therapeutic or diagnostic applications in humans.

References

1.Teichman SL et al., J Clin Endocrinol Metab, 2006 — Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting albumin-bound GHRH analog, in healthy adults
2.Ionescu M, Frohman LA, J Clin Endocrinol Metab, 2006 — Pulsatile GH secretion persists during continuous CJC-1295 stimulation, but the net effect is a sustained, non-pulsatile rise in GH and IGF-1
3.Alba M et al., Am J Physiol Endocrinol Metab, 2006 — Once-daily CJC-1295 (a GHRH analog) normalizes growth in a GHRH-knockout mouse model — mechanistic GHRH-receptor activation
4.Brinkman JE et al., StatPearls (NCBI Bookshelf), 2023 — Physiology, Growth Hormone — GH/IGF-1 axis, pulsatile secretion, and downstream signalling
5.Ayuk J, Sheppard MC, Postgrad Med J, 2006 — Growth hormone and its disorders — physiology and risks of GH/IGF-1 excess